Everything below concerns NR1D1. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-07-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Micelles form only when the concentration of surfactant is greater than the critical micelle concentration (CMC), and the temperature of the system is greater than the critical micelle temperature, or Krafft temperature. The formation of micelles can be understood using thermodynamics: Micelles can form spontaneously because of a balance between entropy and enthalpy. In water, the hydrophobic effect is the driving force for micelle formation, despite the fact that assembling surfactant molecules is unfavorable in terms of both enthalpy and entropy of the system. At very low concentrations of the surfactant, only monomers are present in solution. As the concentration of the surfactant is increased, a point is reached at which the unfavorable entropy contribution, from clustering the hydrophobic tails of the molecules, is overcome by a gain in entropy due to release of the solvation shells around the surfactant tails. At this point, the lipid tails of a part of the surfactants must be segregated from the water. Hence, they start to form micelles. In broad terms, above the CMC, the loss of entropy due to assembly of the surfactant molecules is less than the gain in entropy by setting free the water molecules that were "trapped" in the solvation shells of the surfactant monomers. Also important are enthalpic considerations, such as the electrostatic interactions that occur between the charged parts of surfactants.
=== Inference === Variant genetic codes used by an organism can be inferred by identifying highly conserved genes encoded in that genome, and comparing its codon usage to the amino acids in homologous proteins of other organisms. For example, the program FACIL infers a genetic code by searching which amino acids in homologous protein domains are most often aligned to every codon. The resulting amino acid (or stop codon) probabilities for each codon are displayed in a genetic code logo. As of January 2022, the most complete survey of genetic codes is done by Shulgina and Eddy, who screened 250,000 prokaryotic genomes using their Codetta tool. This tool uses a similar approach to FACIL with a larger Pfam database. Despite the NCBI already providing 27 translation tables, the authors were able to find new 5 genetic code variations (corroborated by tRNA mutations) and correct several misattributions. Codetta was later used to analyze genetic code change in ciliates.
is the differential that defines the integral over the whole volume of the system. The continuity equation for the mass is part of the Euler equations of fluid dynamics. Many other convection–diffusion equations describe the conservation and flow of mass and matter in a given system. In chemistry, the calculation of the amount of reactant and products in a chemical reaction, or stoichiometry, is founded on the principle of conservation of mass. The principle implies that during a chemical reaction the total mass of the reactants is equal to the total mass of the products. For example, in the following reaction
Sources: en.wikipedia.org
Young's modulus (or the Young modulus) is a mechanical property of solid materials that measures the tensile or compressive stiffness when the force is applied lengthwise. It is the elastic modulus for tension or axial compression. Young's modulus is defined as the quotient of the stress (force per unit area) applied to the object and the resulting axial strain (a dimensionless quantity that quantifies relative deformation) in the linear elastic region of the material. As such, Young's modulus is similar and proportional to the spring constant in Hooke's law, but with dimensions of pressure instead of force per distance. Although Young's modulus is named after the 19th-century British scientist Thomas Young, the concept was developed in 1727 by Leonhard Euler. The first experiments that used the concept of Young's modulus in its modern form were performed by the Italian scientist Giordano Riccati in 1782, pre-dating Young's work by 25 years. The term modulus is derived from the Latin root term modus, which means measure.
In 1998, Andrew Fire at Carnegie Institution for Science in Washington DC and Craig Mello at University of Massachusetts in Worcester discovered the RNAi mechanism while working on gene expression in the nematode, Caenorhabditis elegans. The two won the Nobel prize for their research with RNAi in 2006. siRNA and its role in post-transcriptional gene silencing (PTGS) was discovered in plants by David Baulcombe's group at the Sainsbury Laboratory in Norwich, England, a discovery reported in Science in 1999. Thomas Tuschl and colleagues soon reported in Nature that synthetic siRNAs could induce RNAi in mammalian cells. These discoveries led to a surge in interest in harnessing RNAi for biomedical research and drug development. As of 2017, human applications of siRNA had faced significant roadblocks to their success, one of these being "off-targeting". As that decade came to a close, the possibility that these therapies could trigger innate immunity had been discussed. As of 2019, animal models had not been successful in accurately representing the extent of this response in humans; hence, studying the effects of siRNA therapies has been a challenge. As of 2025, seven siRNA-based drugs have received approval from the U.S. Food and Drug Administration (FDA), spanning indications including hypercholesterolaemia, acute hepatic porphyria, primary hyperoxaluria, transthyretin amyloidosis, and haemophilia A and B.
The slide shows at (1) an epithelial cell infected by Chlamydia pneumoniae; their inclusion bodies shown at (3); an uninfected cell shown at (2) and (4) showing the difference between an infected cell nucleus and an uninfected cell nucleus. Epithelium grown in culture can be identified by examining its morphological characteristics. Epithelial cells tend to cluster together, and have a "characteristic tight pavement-like appearance". But this is not always the case, such as when the cells are derived from a tumor. In these cases, it is often necessary to use certain biochemical markers to make a positive identification. The intermediate filament proteins in the cytokeratin group are almost exclusively found in epithelial cells, so they are often used for this purpose. Cancers originating from the epithelium are classified as carcinomas. In contrast, sarcomas develop in connective tissue. When epithelial cells or tissues are damaged from cystic fibrosis, sweat glands are also damaged, causing a frosty coating of the skin.
Sources: en.wikipedia.org
=== Regulatory flexibility === Emergency regulatory pathways created during the pandemic demonstrated the potential for more flexible oversight frameworks. The FDA's Emergency Use Authorizations for COVID-19 tests expanded point-of-care and over-the-counter testing options, establishing precedents that may influence future regulatory approaches for other diagnostic tests.
== History == Nalbuphine was first synthesized in 1965 and was introduced for medical use in the United States in 1979. In the search for opioid analgesics with less abuse potential than pure MOR agonist opioids, a number of semisynthetic opioids were developed. These substances are referred to as mixed agonist–antagonists analgesics. Nalbuphine belongs to this group of substances. The mixed agonists-antagonists drug class exerts their analgesic actions by agonistic activity at the KOR. While all drugs in this class possess MOR antagonistic activity leading to less abuse potential, nalbuphine is the only approved drug in the mixed agonist–antagonist class listed in terms of its pharmacological actions and selectivities on opioid receptors as a MOR partial agonist or antagonist as well as a KOR agonist (Gustein et al. 2001). Nubain was approved for marketing in the United States in 1978 and remains as the only opioid analgesic of this type (marketed in the U.S.) not controlled under the Controlled Substances Act (CSA). When the Controlled Substances Act (CSA) was enacted in 1971, nalbuphine was placed in schedule II. Endo Laboratories, Inc. subsequently petitioned the DEA to exclude nalbuphine from all schedules of the CSA in 1973. After receiving a medical and scientific review and a scheduling recommendation from the Department of Health, Education and Welfare, forerunner to the Department of Health and Human Services, nalbuphine was removed from schedule II of the CSA in 1976. Presently, nalbuphine is not a controlled substance under the CSA.
== History == Vaccine storage was first developed in the early 1960s, when the infectious smallpox disease outbreaks. During this time, vaccine technology was available and offered for protection. Since smallpox has been one of the deadliest diseases known, the World Health Organization (WHO) prepared to launch a campaign to spread the vaccines and end smallpox in 1966. It was not until 1974 where WHO first introduced the Expanded Programme on Immunization (EPI). The main goal was to make immunization available to every child worldwide by 1990. Immunization of six illnesses was being transported, including tuberculosis, diphtheria, pertussis, tetanus, measles, and polio. Dr. Rafe Henderson, the first director of EPI, designed a plan to deliver temperature-sensitive vaccines across dozens of countries safely. It was an important step to ensure that the vaccines were maintained in their determined conditions and guides towards the development of the cold chain. The WHO supported countries worldwide to ensure the vaccine cold chain is maintained. The cold chain has been implemented for years. After EPI was initiated, over 700,000 measles deaths were prevented, and millions of the target diseases have been prevented. There has been a huge milestone in the vaccine industry as scientists create more vaccines for new types of diseases. Therefore, it has a direct impact on the cost of transportation and different kinds of refrigerator storage either at +2° to +8 °C or +20° to +25 °C.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.